GLOBAL ALLAN-HERNDON-DUDLEY SYNDROME TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) market size is expected to reach US$ 17.5 Mn by 2030, from US$ 12 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 5.5% during the forecast period.

Allan-Herndon-Dudley syndrome (AHDS) is a rare genetic disorder caused by mutations in the MCT8 gene. These mutations result in impaired thyroid hormone transport across the blood-brain barrier. Current treatment options for AHDS are limited and aim to manage symptoms. The first line of treatment involves thyroid hormone replacement therapy with triiodothyronine (T3). T3 supplements help restore thyroid hormone levels in the brain to improve neurological development and function. However, high T3 doses sometimes cause side effects like tremors, hyperactivity, and irregular heartbeat. The other option is thyroxine (T4) therapy which relies on the peripheral conversion of T4 to active T3 within cells. This indirect method of treatment is not very effective as the MCT8 mutations disrupt hormone transportation and activation.

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Regional Insights

• North America is expected to be the largest market for Allan-Herndon-Dudley Syndrome (AHDS) during the forecast period, accounting for over 35.7% of the market share in 2023. North America has established itself as the dominant regional market for Allan-Herndon-Dudley syndrome (AHDS). This is due to a strong healthcare infrastructure and expenditure in countries like the U.S. along with the widespread presence of major manufacturers operating production facilities in the region.
• Asia Pacific is expected to be the second-largest market for Allan-Herndon-Dudley syndrome (AHDS), accounting for over 25.2% of the market share in 2023. The Asia Pacific region has emerged as the fastest expanding Allan-Herndon-Dudley syndrome (AHDS) market globally. Countries like China, India, Japan, and South Korea have growing healthcare needs of their large and rapidly developing populations.
• Europe is expected to be the fastest-growing market for Allan-Herndon-Dudley syndrome (AHDS), with a share of 19% during the forecast period. The growth of the market in Europe is due to the increasing prevalence of the disease in the region.

Figure 1. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Analyst’s Views: The global allan-herndon-dudley syndrome (AHDS) (MCT8 deficiency) treatment market is expected to grow at a rapid pace owing to breakthrough in clinical research which can lead to the approval of prominent treatment for the disease. Moreover, some market players are getting orphan drug designations.

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Drivers

• Increasing Prevalence of AHDS: Increasing prevalence of AHDS is expected to drive the market growth over the forecast period. For instance, according to the data published by the National Library of Medicine, Allan-Herndon-Dudley syndrome appears to be a rare disorder. About 25 families with individuals affected by this condition have been reported worldwide.
• Increasing Healthcare Expenditure Globally: Increasing healthcare expenditure globally will aid in the market growth over the forecast period. For instance, according to the data published by the World Health Organization (WHO) on December 8, 2022, the global healthcare spending reached to US$ 9 trillion, which is approximately 11% of the global GDP.

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Opportunities

• Growing funding and grants for rare diseases research: The increased funding and grants for rare diseases research provides a major opportunity for the global Allan-Herndon-Dudley syndrome (AHDS) market. Rare diseases are often neglected by big pharmaceutical companies due to very small patient sizes and thus low commercial viability. However, rising government support through grants and incentive programs have significantly boosted rare disease research activities in recent years.

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Trends

• Shift towards targeted therapies: The shift towards targeted therapies is having a significant influence on the global Allan-Herndon-Dudley syndrome (AHDS) market. Traditionally, the treatment for AHDS primarily focused on managing the symptoms through hormone replacement therapy. However, with advancements in understanding the genetic cause of this rare condition, there is a growing focus on the development of targeted therapeutic approaches.

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Restraints

• Lack of awareness about AHDS: A major factor limiting the growth of the global Allan-Herndon-Dudley syndrome (AHDS) treatment market is lack of awareness about the condition. AHDS is an extremely rare genetic disorder and there is low recognition of its symptoms even within the medical community. Due to the rarity of the disease and limitations in diagnostic testing availability, many cases continue to go undiagnosed. This severely restricts patients' access to potential treatment options.

Figure 2. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market Share (%), By Treatment Type, 2023

To learn more about this report, request a free sample copy

Top Companies in the Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market

• Rare Thyroid Therapeutics International AB
• Erasmus Medical Center

Definition: Allan-Herndon-Dudley syndrome (AHDS) — also known at MCT8 deficiency — is a rare genetic disorder that affects a child's cognition, mobility, and overall health.